non-small cell lung cancer
Conditions
Interventions
Experimental group:CalliSpheres microsphere chemoembolization with simultaneous intravenous chemotherapy
Control group:Systemic intravenous chemotherapy
Sponsors
Lishui Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 70 years; 2. Pathological diagnosis is clear, patients with stage IV lung cancer extracranial oligometastasis who are unable or unwilling to undergo surgery, less than 5 metastases; newly diagnosed and retreated patients with adjuvant chemotherapy or radiotherapy while the recurrence time was more than 1 year; 3. Tissue or plasma gene testing of common lung cancer driving genes such as EGFR, ALK, ROS, RET, HER2, MET and BRAF was negative. Or those without reachable targeted drugs or cannot tolerate targeted drugs; 4. Measurable lesions with observable evaluation (on CT images, lesions >=1 cm); 5. Absolute neutrophils >=2.0x10^9 /L, platelet >= 100x10^9 /L, hemoglobin >= 90g /L; coagulation function: prothrombin time < 15 seconds, partial thromboplastin time < 50S; renal function: creatinine, urea nitrogen normal; liver function: transaminase does not exceed 3 times of normal high limit; normal electrocardiogram; no active infection; 6. Expected survival time is more than 3 months; 7. Good physical condition, ECOG PS score 0 to 2 points; 8. Patient and family informed consent and signed informed consent consent.
Exclusion criteria
Exclusion criteria: 1. Pregnancy, lactating women or family planning patients of reproductive age; 2. Severe heart, liver and kidney dysfunction; 3. Who is expected to be unable to tolerate treatment; 4. Multiple nodules in the lung, single Pulmonary>3, double lung>5; 5. Definite brain metastasis; 6. Pulmonary insufficiency, presence of heavier emphysema or pulmonary bullae; unable to tolerate pulmonary puncture.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radical thermal ablation rate of target lesions with oligometastase;Progression-free survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| New lesion appearance time;Overall survival;Quality of Life; | — |
Countries
China
Contacts
Public ContactJiansong Ji
Lishui Central Hospital
Outcome results
None listed